The Cooper Companies, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +25

Cooper Companies (COO) Stock Looks Undervalued On Current Earnings

Company update AI-generated analysis

πŸ“‰ Cooper Companies shares have fallen 40.8% over the past five years despite recent price climbs, creating a valuation reset opportunity.

πŸ’° The stock trades at roughly 20.6x earnings, significantly below the Medical Equipment industry average of 27.0x and peer group average of 24.8x.

πŸ“ˆ Management is focusing on profitable growth and cash flow following reports of flat revenue in late 2026.

βš–οΈ Legal investigations and softer guidance have cooled investor enthusiasm, yet the P/E multiple remains below analyst fair value models.

πŸ’΅ Bull case narrative identifies record Q3 2026 free cash flow and reiterated guidance for US$2.2b annualized FCF (2026-2028) as drivers of a 7% undervaluation.

πŸ“‰ Bear case narrative warns that the transition away from older hydrogel products in Japan and Asia Pacific could weigh on overall CooperVision revenue mix, suggesting 6% overvaluation.

πŸ€– Company-wide efforts to streamline operations through shared services, restructuring, and AI-enabled inventory optimization aim to improve working capital efficiency.

πŸ‘οΈ Community sentiment is split between investors who see premium lenses and cash flow as underappreciated versus those believing expectations remain too generous.

Bullish Signals
  • Cooper Companies trades at a P/E of roughly 20.6x, which is below the Medical Equipment industry average of 27.0x and the peer group average of 24.8x.
  • The company recorded record free cash flow in Q3 2026 and reiterated guidance for approximately US$2.2b of free cash flow over the 2026 to 2028 period.
  • Management is executing company-wide efforts to streamline operations through shared services, restructuring, and AI-enabled inventory optimization to improve working capital efficiency.
  • Strong demand for daily silicone hydrogel lenses and premium products like MyDay multifocal and Energys is currently supporting solid contact lens revenue.
Risk Factors
  • Ongoing legal investigations and softer guidance have clearly cooled investor enthusiasm regarding the company's stock.
  • The transition away from older hydrogel products in Japan and other parts of Asia Pacific could weigh on the overall CooperVision revenue mix.
  • Recent reports indicate flat revenue, requiring investors to carefully assess how fast earnings can improve relative to current share price pressure.
Full Analysis
Cooper Companies (COO) stock has recently climbed despite weak longer-term returns and a 40.8% share price decline over the past five years, prompting an analysis of whether current valuations align with earnings. The article highlights that recent reports indicate flat revenue, though management is focusing on profitable growth and cash flow generation. Valuation metrics suggest COO trades at approximately 20.6x earnings, which is below the Medical Equipment industry average of 27.0x and lower than the peer group average of 24.8x. Analysts note that despite legal investigations and softer guidance cooling enthusiasm, the P/E multiple remains discounted relative to a blended fair value model accounting for margins and scale. Simply Wall St presents two divergent narratives: a bull case citing 7% undervaluation driven by operational streamlining, record Q3 2026 free cash flow, and reiterated guidance of roughly US$2.2b in free cash flow for 2026-2028; and a bear case suggesting 6% overvaluation due to the transition away from older hydrogel products in Asia Pacific weighing on revenue mix. The article concludes that while demand for daily silicone hydrogel lenses supports solid contact lens revenue, future performance depends on execution of restructuring efforts and AI-enabled inventory optimization. The debate centers on whether the market has adequately priced in the potential for improved working capital efficiency and higher free cash flow yields amidst ongoing legal scrutiny.